CN107849126B - 仅有重链的抗ang-2抗体 - Google Patents

仅有重链的抗ang-2抗体 Download PDF

Info

Publication number
CN107849126B
CN107849126B CN201680044324.2A CN201680044324A CN107849126B CN 107849126 B CN107849126 B CN 107849126B CN 201680044324 A CN201680044324 A CN 201680044324A CN 107849126 B CN107849126 B CN 107849126B
Authority
CN
China
Prior art keywords
ang
antibody
antibodies
hcab
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680044324.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849126A (zh
Inventor
Y·梁
D·W·吉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN107849126A publication Critical patent/CN107849126A/zh
Application granted granted Critical
Publication of CN107849126B publication Critical patent/CN107849126B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680044324.2A 2015-07-29 2016-07-29 仅有重链的抗ang-2抗体 Expired - Fee Related CN107849126B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562198518P 2015-07-29 2015-07-29
US62/198,518 2015-07-29
US201562205185P 2015-08-14 2015-08-14
US62/205,185 2015-08-14
PCT/US2016/044838 WO2017020001A2 (en) 2015-07-29 2016-07-29 Heavy chain only antibodies to ang-2

Publications (2)

Publication Number Publication Date
CN107849126A CN107849126A (zh) 2018-03-27
CN107849126B true CN107849126B (zh) 2022-04-08

Family

ID=56610025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044324.2A Expired - Fee Related CN107849126B (zh) 2015-07-29 2016-07-29 仅有重链的抗ang-2抗体

Country Status (13)

Country Link
US (3) US10266589B2 (enExample)
EP (2) EP3792279A3 (enExample)
JP (1) JP6916776B2 (enExample)
CN (1) CN107849126B (enExample)
AU (2) AU2016298398A1 (enExample)
BR (1) BR112018001762A2 (enExample)
CA (1) CA2992660A1 (enExample)
DK (1) DK3328886T3 (enExample)
ES (1) ES2828694T3 (enExample)
HU (1) HUE051165T2 (enExample)
PL (1) PL3328886T3 (enExample)
RU (1) RU2749674C2 (enExample)
WO (1) WO2017020001A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
JP2018523673A (ja) * 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CA3196549A1 (en) * 2020-11-04 2022-05-12 Bahram Valamehr Engineered ipsc and immune effector cells for heterogenous tumor control
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131078A1 (en) * 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to vegf and ang2
CN102906114A (zh) * 2010-03-26 2013-01-30 霍夫曼-拉罗奇有限公司 双特异性二价抗vegf/抗ang-2抗体
WO2013144266A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Ang2-binding molecules
WO2014072876A1 (en) * 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CN103936860A (zh) * 2008-10-08 2014-07-23 霍夫曼-拉罗奇有限公司 双特异性抗-vegf/抗-ang-2抗体
CN104395339A (zh) * 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CN104428315A (zh) * 2012-07-13 2015-03-18 罗氏格黎卡特股份公司 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
PL223153B1 (pl) 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
EP2457578B1 (en) * 2004-09-28 2015-08-19 Aprogen, Inc. Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction
JP4884395B2 (ja) * 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CA2746395C (en) * 2008-12-10 2019-07-09 Ablynx N.V. Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
EP2832746B1 (en) * 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-Ang2 antibody
KR102146845B1 (ko) * 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
SG11201703426PA (en) * 2014-11-10 2017-05-30 Hoffmann La Roche Anti-pdgf-b antibodies and methods of use
WO2017020001A2 (en) * 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
JP2018523673A (ja) * 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936860A (zh) * 2008-10-08 2014-07-23 霍夫曼-拉罗奇有限公司 双特异性抗-vegf/抗-ang-2抗体
CN102906114A (zh) * 2010-03-26 2013-01-30 霍夫曼-拉罗奇有限公司 双特异性二价抗vegf/抗ang-2抗体
WO2012131078A1 (en) * 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to vegf and ang2
CN103562222A (zh) * 2011-04-01 2014-02-05 勃林格殷格翰国际有限公司 结合VEGF和Ang2的双特异性结合分子
WO2013144266A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Ang2-binding molecules
CN104395339A (zh) * 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
CN104428315A (zh) * 2012-07-13 2015-03-18 罗氏格黎卡特股份公司 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用
WO2014072876A1 (en) * 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy;Yvonne Kienast等;《Clinical Cancer Research》;20131231;第19卷(第24期);6730-6740 *
双功能抗体药物研究进展;李锋等;《中国医药生物技术》;20140831;第9卷(第4期);291-293 *

Also Published As

Publication number Publication date
JP6916776B2 (ja) 2021-08-11
WO2017020001A2 (en) 2017-02-02
CN107849126A (zh) 2018-03-27
US20210324064A1 (en) 2021-10-21
RU2018103960A3 (enExample) 2020-01-16
EP3328886B1 (en) 2020-09-16
EP3328886A2 (en) 2018-06-06
RU2749674C2 (ru) 2021-06-16
US10266589B2 (en) 2019-04-23
HUE051165T2 (hu) 2021-03-01
US11046756B2 (en) 2021-06-29
EP3792279A3 (en) 2021-07-07
JP2018527327A (ja) 2018-09-20
HK1253947A1 (en) 2019-07-05
AU2016298398A1 (en) 2018-02-08
US20170107279A1 (en) 2017-04-20
US20190248882A1 (en) 2019-08-15
BR112018001762A2 (pt) 2018-09-18
ES2828694T3 (es) 2021-05-27
RU2018103960A (ru) 2019-08-28
PL3328886T3 (pl) 2021-02-08
AU2022259761A1 (en) 2022-12-01
EP3792279A2 (en) 2021-03-17
CA2992660A1 (en) 2017-02-02
DK3328886T3 (da) 2020-11-02
WO2017020001A3 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
CN107849126B (zh) 仅有重链的抗ang-2抗体
US20250333490A1 (en) Heavy chain only antibodies to pdgf
MX2014004449A (es) Tratamiento de enfermedad ocular.
CN106459210A (zh) 用于治疗糖尿病黄斑性水肿的组合物和方法
WO2022199603A1 (en) Antibody fusion proteins and uses thereof
WO2018175319A1 (en) Heavy chain only antibodies to vegf
US8163285B2 (en) Nogo-A binding molecules and pharmaceutical use thereof
TW202506728A (zh) 活化素a受體樣1型(alk1)之雙特異性促效性抗體
HK1253947B (en) Heavy chain only antibodies to ang-2
JP7691976B2 (ja) 抗Ｎｒｐ１Ａ抗体及びその眼又は眼部疾患を治療するための使用
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法
WO2023083243A1 (zh) 一种抗il-17/vegf双功能融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220408